| Literature DB >> 19336961 |
Yuko Kato-Motozaki1, Kiyonobu Komai, Kazuya Takahashi, Chiho Ishida, Masami Ueda, Susumu Kusunoki, Masahito Yamada.
Abstract
Polyethylene glycol-interferon alpha (PEG-IFNalpha) has been used as the standard treatment for hepatitis C virus (HCV) infection. There have been no previous reports of polyradiculoneuropathy with anti-ganglioside antibodies induced by PEG-IFNalpha-2b. We report a 59-year-old man who developed polyradiculoneuropathy during treatment with PEG-IFN alpha-2b for chronic HCV infection. Serum levels of anti-asialo-GM1 (GA1) and anti-GM1 antibodies were elevated. Cessation of therapy with double filtration plasmapheresis resulted in marked improvement in his symptoms accompanied by a reduction in the antibody level. PEG-IFN alpha-2b may induce peripheral neuropathy mediated by anti-GA1 and anti-GM1 antibodies.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19336961 DOI： 10.2169/internalmedicine.48.1794
Source DB: PubMed Journal: Intern Med ISSN： 0918-2918 Impact factor: 1.271